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Review     
Vascular neurocognitive disorders and 
the vascular risk factors 
 Carmen V. Albu1, Vlad Pădureanu2*, Mihail V. Boldeanu3, Ana M. Bumbea4, Anca 
Ş. Enescu2, Dana M. Albulescu5, Cristian A. Siloși6, Aurelia Enescu2   
 1Department of Neurology, 2Department of Internal Medicine, 3Department of Immunology, 
4Department of Physical Medicine and Balneology, 5Department of Radiology/ Medical Imaging, 
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Abstract Dementias are clinical neurodegenerative diseases characterized by permanent and 
progressive transformation of cognitive functions such as memory, learning capacity, 
attention, thinking, language, passing judgments, calculation or orientation. Dementias 
represent a relatively frequent pathology, encountered at about 10% of the population of 65-
year olds and 20% of the population of 80-year olds.  
This review presents the main etiological forms of dementia, which include Alzheimer 
form of dementia, vascular dementia, dementia associated with alpha-synucleionopathies, and 
mixed forms. Regarding vascular dementia, the risk factors are similar to those for an 
ischemic or hemorrhagic cerebrovascular accident: arterial hypertension, diabetes mellitus, 
dyslipidemia, smoking, obesity, age, alcohol consumption, cerebral atherosclerosis/ 
arteriosclerosis.  
Several studies show that efficient management of the vascular risk factors can prevent the 
expression and/ or progression of dementia. Thus, lifestyle changes such as stress reduction, 
regular physical exercise, decreasing dietary fat, multivitamin supplementation, adequate 
control of blood pressure and serum cholesterol, and social integration and mental stimulation 
in the elderly population are important factors in preventing or limiting the symptoms of 
dementia, a disease with significant individual, social, and economic implications.  
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Highlights: 
 
✓ Dementia is a neurocognitive disorder with multiple and severe (individual, social, and 
economic) implications. 
✓ Lifestyle changes implying stress reduction, regular physical exercise, decreasing 
dietary fat, social integration and mental stimulation in the elderly population are 
important factors in preventing or limiting the symptoms of dementia    
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Introduction 
Neuro-cognitive disorders (NCD) are 
neurodegenerative diseases characterized clinically by 
persistent and progressive impairment of cognitive 
functions (1). These impairments are usually inherited, 
with etiology and pathogeny currently documented, but 
they are not considered developmental disorders (2).       
According to the American Psychiatric Association 
and The Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM5), the term dementia was 
replaced with the notion of major neurocognitive 
disorder (NCD), defining thus a broad spectrum of 
cognitive and functional disorders that form the basis for 
diagnostic criteria. Nevertheless, for certain etiological 
subtypes, the term of dementia is standard (2). Thus, 
according to the current international agreement, for the 
confirmation of a major neurocognitive disorder, the 
cognitive deficiency and the main clinical SDR (source 
data review) must be characterized by a significant 
decline in performance compared to a previous level in 
one or more cognitive fields such as: memory, learning, 
complex attention, executive function, perceptual-motor 
skills related to language skills, or social knowledge. The 
cognitive deficiency must interfere with daily activities, 
and the health care provider might request evidence of 
minimum assistance for daily routines (e.g., invoices, 
payment, testimonials from relatives, etc.). At the same 
time, the cognitive deficiency must not be associated 
with a psychological disorder, such as a major depression 
or schizophrenia. (3).  
This paper presents the main etiological forms of 
dementia, focusing discussion especially on vascular 
neurocognitive disorder and the vascular risk factors 
implicated (diabetes mellitus, age and arterial 
hypertension, the metabolic syndrome, smoking and 
alcohol consumption), as a premise to further understand 
and develop therapeutic and prophylactic guidance 
related to this severe disease. 
 
Discussion 
DSM5 defines the incipient stage of dementia when 
the cognitive disorder is less severe as a minor 
neurocognitive disorder. Several diagnostic criteria are 
also formulated for this incipient stage. The subtypes of 
minor or major NCD are: NCD due to Alzheimerʼs 
disease, vascular NCD, NCD with Lewy bodies, NCD 
due to Parkinsonʼs disease, frontotemporal NCD, NCD 
due to traumatic brain injury, NCD due to HIV infection, 
substance/ medication-induced NCD, NCD due to 
Huntingtonʼs disease, NCD due to prion disease, NCD 
due to another medical condition, NCD due to multiple 
etiologies, and unspecified NCD (1, 2). 
Regarding their global prevalence, dementias, a term 
almost super-imposable with major NCD, represent 1-
2% of the population of 65 and older, and 30% by age 85 
(3). Estimations of the prevalence of minor NCD for the 
older patients range between 2-10% at the age 65 and 5-
25% at the age 85 (2). The most common etiological 
factors are represented by: Alzheimer disease (60%–
80%), dementia with Lewy bodies, Parkinson disease 
with dementia (10%–20%), frontotemporal dementia 
(5%–10%), cerebrovascular disease (10%– 20%) (4).  
Vascular neurocognitive disorder is the result of 
reduced cerebral blood flow that can either produce an 
ischemic stroke, with different strategic localizations at 
the cerebral level (such as the angular gyrus, the 
temporal lobe, the frontal lobe, the thalamus, the caudate 
nucleus, the hippocampus), or result in modifications 
such as the hyaline and fibrosis of the small vessels with 
the appearance of infarcts at the level of the cerebral 
white matter (clinically silent or accompanied by 
neurological non-specific signs). These injuries of the 
white matter generate interruptions of the cortical and 
subcortical circuits, with the deterioration of complex 
attention, information processing speed, and executive 
skills and abilities, resulting in a neurocognitive disorder 
(5-7). At the same time, there are also the so-called 
cortical– subcortical border zone infarcts, the result of 
hypoperfusion from atherosclerosis, as well as extended 
episodes of arterial hypotension that can be accompanied 
by NCD. Consequently, neurocognitive disorders having 
as etiology the cerebrovascular diseases actually 
represent a vast group of manifestations from the 
cognitive vascular sphere. They are characterized by two 
subcategories: medium or major NCD (7).    
The major vascular NCD represents the second most 
frequent cause of NCD, second only to Alzheimer 
disease. In the USA, the prevalence of vascular dementia 
is 0,2% for those between 65-70 years, and more than 
16% for those over 80. In the first three months after a 
stroke, about 20-30% of the patients are diagnosed with 
dementia. Regarding patients with neurological 
pathology, the prevalence of vascular dementia increases 
from 13% at age 70 to 44,6% at age 90, compared to the 
Alzheimer disease (23,6%-51%), and to vascular 
dementia associated with the Alzheimer disease (2% - 
46,4%). The prevalence is higher for men and Afro-
Americans, compared to Caucasians and East Asians (2, 
3).  
The revised NINDS-AIRENS criteria (National 
Institute of Neurological Disorders and Stroke-
Association Internationale pour la Recherche et 
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ischemic scale (8, 9) have been unanimously accepted 
and used by neurologists for diagnosing vascular 
dementia. Initially, dementia related to the vascular 
traumas or injuries was labeled arteriosclerotic dementia, 
then multi infarct dementia, post-stroke dementia, and 
vascular dementia; the term currently used is vascular 
cognitive disorder (7). A correct diagnosis typically 
requires a fairly complicated algorithm. The DSM5 
diagnostic criteria elaborated by the American 
Psychiatric Association are also formulated.     
 The main types of the vascular neurocognitive 
disorder are as follows (10): 
1. Cortical vascular dementia or multi infarct dementia, 
(Multi-infarct Dementia), characterized by the presence 
of infarcts in the cortical and subcortical regions of the 
cerebral arteries and clinically by the existence of motor 
deficits, unilateral sensitivity disorders, and the gross 
occurrence of cognitive decline and aphasia. 
2. Subcortical vascular dementia or the dementia of 
small bloood vessels, (Subcortical Ischemic Vascular 
Dementia or Bisswangerʼs Disease), a condition of 
cerebral insufficiency and Bisswangerʼs disease, 
clinically characterized by pure motor deficits, signs of 
bulbar palsy, dysarthria emotional lability, or deficits of 
executive functions. 
3. Cortical and subcortical vascular dementia, (Mixed 
Dementia) with mixed components. 
4. Strategic infarction dementia involving the strategical 
spheres of the brain such as the thalamus, hippocampus, 
fronto-cingulate cortex, temporal lobe-median area, and 
basal portion of the brain (1, 7-9). 
5. Other types of vascular dementia are: vasculits, 
cerebral amyloid angiopathy (CAA), and hereditary 
disease such as CADASIL (Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts And 
Leukoencefalopathy).  
 The last type is an hereditary affectation with 
autosomal transmission (mutations of the Notch3 gene 
from the 19 chromosome that codifies a dominant 
transmembrane receptor that is to be found in the 
vascular flat muscle and at the level of the pericytes, in 
the case of the adults) that is rarely encountered. It is 
clinically associated with: progressive dementia, mood 
disorders, migraine with aura, and recurrent subcortical 
cerebral infarctions (10, 11). The cerebral amyloid 
angiopathy (CAA) affects persons over 65, and shows an 
increased incidence for those 80-90 years old.  
 Other types of vascular neurocognitive disorder are 
(7):        
1. Post-ischemic encephalopathy that is divided into 3 
subentities: 
o the cortical laminar necrosis, localized in the areas 
of arterial border associated with the diffuse deterioration 
of white matter; 
o multiple post-ischemic injuries that have as a 
substratum the hypotension and enlargement of the 
vascular wall with the reduction of the cerebral blood 
flow and the generation of minor cortical and subcortical 
infarctions; 
o hippocampal sclerosis characterized at the 
neuropathological level by neuronal loss and gliosis, 
noticed in patients over 85 years olds who were not 
previously affected by the Alzheimerʼs dementia, but 
with pathological antecedents of cardiac insufficiency 
and cerebral hypoperfusion.     
2. Hemorrhagic dementia. Cerebral bleedings do not 
regularly cause dementias. However, there may be a 
connection between cerebral bleedings and NCD, 
depending on its localization and/or dimension, or in the 
case of cortical and subcortical hemorrhages, whether the 
patient had arterial hypertension antecedents. According 
to several hypotheses, several mechanisms might explain 
the appearance and development of certain 
neurocognitive disorders for patients affected by a 
stroke, such as (5, 6, 12):  
o the cerebral injuries determined by an ischemic or 
hemorrhagic stroke, involving neurological deficits 
(motor deficits, sensitivity, language or sight disorders, 
etc.) can result in perturbations of superior nervous 
functions, having as clinical expression minor or major 
neurocognitive disorders; 
o after an ischemic or hemorrhagic stroke, the 
neurocognitive disorder may actually be a continuation 
of a preexistent state, such as the Alzheimer dementia, 
not made known by the patient, or not diagnosed before 
the cerebrovascular event; 
o the recidivated ischemic stroke can lead to the 
development of the neurocognitive disorders; as is well 
known, multiple ischemic attacks can favor the 
development of certain cognitive disorders characterized 
by a rapid progressive model (multi infarction dementia). 
These hypotheses are supported by the fact that an 
ischemic stroke is associated with two physio- 
pathological mechanisms: 
1. Arterial enlargement with the consecutive narrowing 
of the lumen, modifications resulting from factors such 
as arterial hypertension, certain diseases, dyslipidemia, 
or genetic factors. These modifications are represented 
by deposits of fibrinoid, the hypertrophy of the flat 
musculature, and other elements of conjunctive tissue 
present in the arterial wall, a phenomenon called 
fibrinoid degeneration and lipohyalinosis (11).  
2. Obstruction of the origins of penetrating arteries by 
parent large intracranial artery intimal plaques. It has 
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been noticed that these modifications of the cerebral 
large blood vessels are much more important for the 
determination of a stroke than the intrinsic injury of the 
small blood vessels. Thus, the decrease in the blood flow 
in the cerebral small arteries or their obstruction is 
generated either by the existence of the atheroma plaque, 
that can be situated at the level of the large cerebral 
blood vessels, or by the existence of the microatheromas 
that can be found precisely on the place of origin of the 
small arteries. The atheroma plaque initially takes shape 
by the enlargement of the main blood vessels followed 
by the deposition of the lipids in the blood, the 
accumulation of lipid laden macrophages, cholesterol 
crystals and the deposition of calcium at the level of the 
main blood vessels.  
 This process is accompanied by a local 
inflammatory reaction that includes lymphocytes and 
macrophages, with the loss of the elasticity specific to 
the arterial wall, the narrowing and then the occlusion of 
the arterial lumen. The atheroma plaque can break and 
injure the distal cerebral arteries (11). The described 
atherosclerotic mechanism can combine with the 
thrombotic one, and this steno-occlusive mechanism of 
the small blood vessels is favored by: the increased 
resistance of the blood vessels to the blood flow, the 
denatured vascular self-adjustment, the modifications of 
the hematoencephalic barrier, the modifications of the 
vascular endothelium, and the dilation of the perivascular 
spaces (10). Thus, both minor ischemic lesions, (lacunar 
strokes) with a diameter ranging between 1-15 mm and 
anomalies at the cerebral white matter take place at the 
level of the brain, due to the demyelination of the myelin 
sheath and consequently of the axons and deterioration 
of the oligodendrocytes, but without the development of 
profound infarctions or cystic necrosis (10, 11).  
 The most frequent localizations of the lacunar 
strokes are: the putamen, the pallidum, thalamus, caudate 
nucleus, the internal boll and the corona radiata, the 
cerebral trunk, and the cerebellar white matter. The 
association between these minor strokes and 
modification of the white matter represent the 
Bisswanger disease (7, 11). The large number of lacunae 
associated with the injuries of white matter determines 
interruptions of the prefrontal-subcortical, thalamo-
cortical, striato-cortical circuits, as well as deterioration 
of the limbic system, structures that play specific roles in 
cognition, memory, and behaviour, thus being 
responsible for the development of the neurocognitive 
disorders (7, 11). However, it seems that the 
accumulation of b–amyloid and of the neurofibrillary 
tangles, specific to the Alzheimer disease, can facilitate 
and accelerate the development of the cerebral ischemic 
lesions and then of the neurocognitive disorders (10). It 
is well known that the cholinergic system plays a role in 
the adjustment of the cerebral blood flow. Its dysfunction 
can lead to the reduction of blood flow and thus to the 
development of the cerebral hypoperfusion, representing 
a risk factor for the production of the cognitive decline.       
o Significant hemodynamic stenosis of the large 
cerebral blood vessels affected by atherosclerosis or 
arteriopathy that affects the small cerebral vessels, 
reducing the cerebral blood flow, without the induction 
of cerebral lesions leads to the development of a 
cognitive deterioration syndrome; this mechanism is not 
sufficiently investigated (3). We also note, in the context 
of the injury of the cerebral microcirculation, the 
existence of the incomplete ischemia and of the selective 
tissue necrosis that are clinically characterized by the 
cognitive decline (13, 14).  
o Structural alterations of the small cerebral blood 
vessels, such as arteriosclerosis, lipohyalinosis, cerebral 
amyloid angiopathy CAA, CADASIL, etc., that can 
determine the lacunar strokes or modifications of the 
typical cerebral white matter seem to be responsible for 
the development of certain cognitive disorders similar to 
those related to subcortical vascular dementia (15-17). At 
the level of the small blood vessels, apart from the 
fibrinoid degeneration and lipohyalinosis, there is also 
the possibility of accumulation of a granular material that 
can infiltrate from the main blood vessels to the tunica 
adventitia of the arterial wall. This aspect is specific to 
the hereditary diseases such as CADASIL. 
Anatomopathological studies have also revealed the 
presence of glycoproteins at the level of the arterial wall, 
whereas the muscle fibres present in the medium tunic 
are hypertrophied, deteriorated, and the vascular 
endothelium can be absent or replaced with the cholagen 
(11). Devoid of the muscle layer, the vascular wall in the 
CAA becomes thicker due to a hyaline, acellular 
material, while the presence of A-beta peptide in persons 
diagnosed with arterial hypertension increases the brainʼs 
vulnerability to the ischemic lesions. It has been 
demonstrated that the CAA rarely causes spontaneous 
cerebral hemorrhages (7).   
There are pathogenic mechanisms that explain the 
development of vascular neurocognitive disorders, 
namely (7): the sedimentation of the amyloid at the 
brainʼs level, the existence of the subdiagnosed 
Alzheimer disease, with a series of studies showing that 
it can coexist with the vascular risk factors. Thus, 
Alzheimer disease associated with the cerebrovascular 
disease has been accepted as a diagnosis (1), the 
phenomenon of growing old, atherosclerosis, the arterial 
hypertension.     
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These pathogenic links bring about the 
cerebrovascular disease and dementia, relying on an 
inflammatory-type mechanism and the oxidative stress at 
the vascular level, mediated by b-amyloid and NADPH, 
(Nicotinamide adenine dinucleotide phosphate) –
OXIDASE, the enzyme that represents in its turn a 
permanent source of oxidative stress at the vascular 
level. The cerebrovascular alterations associated with 
changes in the hematoencephalic barrier increase the 
brainʼs vulnerability to the hypoxic-ischemic 
mechanisms, generating changes to the structure and 
functions of the neurons, accelerating thus the 
development of the neurocognitive disorders. Due to 
their amyloidogenic role, the following etiopathogenic 
factors apoE4, Ɛ2 and Ɛ3 can determine microvascular 
modifications, clinically characteri-zed by 
neurocognitive disorders: the atrial fibrillation that via 
microembolic complications induces various cognitive 
declines and neurological deficits, as a result of the 
microinfarcts in different areas of the brain. 
Inflammation may have a role in the inducement of these 
mechanisms (7).       
Due to the etiopathogenic relation, the 
cerebrovascular disease – neurocognitive disorders have 
a multifactorial etiology, the risk factors involved in its 
development being divided as follows (1, 5, 9): 
o vascular: arterial hypertension, dyslipidemia, 
smoking, generalized atherosclerosis, other heart 
diseases, (myocardial infarction, atrial fibrillation), 
smoking; 
o demographic: age, education; 
o genetic 
o factors related to the stroke, (localization of the 
lesions, the type of stroke, the type of the cerebral 
lesions); 
o the presence of certain factors that can lead to chronic 
cerebral hypoperfusion and ischemic events, (heart 
arrhythmias, heart diseases, or the congestive heart 
failure, etc). 
 
 Diabetes Mellitus  
Diabetes mellitus (DM) represents a major risk 
factor for myocardial infarction, thromboses, and 
cerebrovascular disease—ischemic or hemorrhagic 
stroke, associated with mild or major vascular 
neurocognitive disorders (18). The risk of developing 
dementia doubles in patients diagnosed with DM who 
follow antidiabetes oral drugs or Insulin treatments 
compared to those without DM (19-21). Patients younger 
than 65 diagnosed with diabetes mellitus are at higher the 
risk of vascular dementia than older ones. The risk is 
directly proportional to the duration of the disease, and it 
may appear concomitantly with certain complications of 
the diabetes, such as the peripheral arterial disease (22-
24). Various cognitive disorders can be encountered at 
the level of mild or low values of glycemia (prediabetes) 
(25). Jaffe and collaborators have shown in a 4-year 
prospective study that older women with low blood sugar 
levels have lower scores on cognitive evaluation tests 
than the women with normal values (18). The second 
type of DM (type II) has been associated with an 
increased risk of neurocognitive disorder. This risk 
increases with the increase in the number of repeated 
episodes of hypoglycemia (18). Imagistic investigations 
such as the cranial computed tomography (CT) scan or 
magnetic resonance imaging have emphasized the 
presence of cortical atrophy and a cortical or subcortical 
stroke, as well as several ischemic subcortical 
modifications, or leukoaraiosis in such patients. This 
association is not surprising, considering the fact that 
DM increases the risk of developing a stroke or lacunar 
infarcts (25, 26). The association between DM type 2 and 
arterial hypertension increases the risk of developing 
cerebrovascular diseases. The risk decreases together 
with the decrease in the values of arterial tension (18).   
 
 The age and the arterial hypertension  
It is well known that advanced age (individuals over 
60) is associated with both high blood pressure and 
cerebrovascular disease, which in turn can lead to the 
development of neurocognitive disorders (27). Knowing 
that the risk of ischemic and hemorrhagic stroke accident 
increases with aging leads to the conclusion that age 
represents an important factor in the development of 
vascular dementia. Furthermore, older patients may 
develop cerebral amyloid angiopathy (CAA) that can 
cause multiple cerebral infarcts, lobar hemorrhages or 
microhemorrhages, and subsequent cognitive decline. 
Thus, although dementia may occur at any age, older 
patients are more predisposed (18). This conclusion is 
consistent with epidemiological data: 2% of the 
population aged from 65 to 70 are diagnosed with 
dementia, 5% from 70 to 80 suffer from dementia, and 
20% over 80 and 33% over 90 are diagnosed with 
clinical signs of dementia (28, 29).    
Blood pressure values over 160/95 mmHg represent 
a major risk for the development of a vascular dementia 
(23, 24). Cranial CT scans on hypertensive patients have 
revealed a cortical atrophy or leukoaraiosis at the level of 
the hippocampus (30, 31). High blood pressure that is not 
treated or therapeutically controlled generates 
dysfunctions of the cerebral vessels by modifications of 
the vascular endothelium, of the flat muscle cells from 
this level, and of the hematoencephalic barrier, as well as 
extensive lesions at the level of the cerebral white matter 
that can be associated with the cognitive decline (18, 32).  
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With endothelial modifications such as 
lipohyalinosis (also called the fibrinoid necrosis), a 
hypertrophic remodeling and the eutrophication of the 
cerebral arteries generate arterial thickening, narrowing 
of the vascular lumen, stenosis, or arterial occlusion, as 
well as the reduction or absence of blood flow in a 
certain cerebral area, thus altering the brainʼs capacity to 
adapt to an insufficient energy contribution, induced by 
the reduced or absent blood flow. The mechanisms 
associated with cerebral atherosclerosis in patients 
diagnosed with arterial hypertension result in cerebral 
ischemic lesions with different localizations and 
neurocognitive disorders (33, 34). The increase in the 
pressure of impulse which stands as a marker of arterial 
rigidity has been associated with cognitive decline and 
especially with modifications of linguistic skills and 
abilities (18). Studies or clinical trials developed thus far 
align with the fact that vascular dementia is less frequent 
for hypertensive patients treated with hypotensors than in 
untreated patients (35).  
 
 The metabolic syndrome 
Metabolic syndrome is defined by the presence of at 
several cardiovascular risk factors: obesity, arterial 
hypertension, dyslipidemia (high TG values and low 
values of HDL cholesterol) and DM. Metabolic 
syndrome is associated with an increased risk of 
developing vascular neurocognitive disorders (18), 
especially for patients aged 70 or older (18, 36, 37). At 
the same time, for some male patients with metabolic 
syndrome older than 75, the cognitive decline is slightly 
delayed, explained by a simple neuroprotective effect of 
the metabolic syndrome (38). For middle-aged 
individuals, hypercholesterolemia is associated with an 
increased risk of dementia, whereas for older persons, it 
is associated with a low risk of developing dementia. 
Prospective statistical studies have shown that treatment 
with statins for dyslipidemia does not influence the 
development of neurocognitive disorders (18).       
Certain studies outline the fact that the patients over 
60 with high levels of triglycerides and obesity have a 
high risk of developing short term memory disorders and 
even dementia (28, 39). Persons with a very high body 
mass index (BMI) are also more predisposed to 
developing dementia throughout their life (28, 40). The 
BMI effect modifies with aging (33). Studies on middle-
aged or older populations have shown causal 
relationships among cerebrovascular disease, 
neurocognitive disorder, and vascular risk factors such 
as:  hypertension (41), dyslipidemia (42), DM (43), 
associated with behavioral factors such as obesity and 
the lack of physical activities (44).  
 Smoking 
Clinical studies have found that nicotine can 
stimulate good functioning of certain neurotransmitters 
involved in the generation of the different types of 
dementia and especially of the Alzheimer disease, but 
this relationship may be valid only in the short run. In the 
long run, nicotine can modify the vascular wall, 
modifying at the same time the chemical composition of 
nutritive substances in the blood essential for good 
functioning of brain. 
Statistical studies in the USA on populations over 65 
years of smokers and alcohol consumers have identified 
smoking as an important risk factor for stroke and a 
potential risk factor for cognitive decline (45). A Chinese 
study on a large number of smokers and alcohol 
consumers has demonstrated that smoking is associated 
with a greater risk of developing a vascular 
neurocognitive disorder. Smoking results in a 
pronounced progression of the cerebral vascular lesions 
as well as deterioration of the executive function a 
decade later (46). Thus, smoking is a risk factor for both 
vascular dementia and Alzheimer disease, the smokers 
being twice more likely to develop a certain type of 
dementia (28, 29, 40).   
 Alcohol  
Small quantities of alcohol may protect older 
individuals against dementia and Alzheimer disease. 
Based on several studies, 14 units of alcohol for women 
and a maximum 21 units for men per week are not 
considered excessive (a unit represents a small glass of 
wine or one single measure of alcoholic drinks). The 
American Heart Association stipulates moderate alcohol 
consumption as 1-2 portions of alcohol/day for men and 
one portion/day for women (340g of beer, 113g of wine 
or 40g of alcoholic drinks); exceeding these doses 
increases the risk of stroke and favors other 
cardiovascular risk factors such the arterial hypertension 
and obesity. Thus, moderate quantities of alcohol do not 
eliminate the risk of developing dementia, but they can 
play an important role in its reduction (28, 29, 40). 
According to several large studies of chronic alcohol 
consumers, excess alcohol is associated with the 
cognitive decline of dementia (40). 
The USA study on groups over 65 years 
demonstrated that moderate alcohol consumption 
represents a protective factor only on the vascular 
endothelium, especially for 80 years olds (45). Excessive 
alcohol consumption has neurotoxic effects on the 
central nervous system, thus bringing about dementia 
(45).  The Chinese study on a large number of smokers 
and alcohol consumers has shown that a daily quantity of 
alcohol (beer, wine, hard liquor) is associated with a 
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higher risk of vascular neurocognitive disorder than for 
those who do not consume alcohol. The combination of 
smoking and alcohol consumption leads to a higher risk 
of developing a vascular NCD than moderate, daily 
alcohol consumption or smoking (46). The triad, arterial 
hypertension- smoking – DM, leads to the appearance 
and development of vascular dementia (46). Although 
the effects of alcohol consumption and smoking on 
cognitive function have been confirmed through 
numerous studies, their mechanism of action is yet 
unclear (46).  It has been noticed that male patients, 
alcohol consumers, and carriers of the apolipoprotein E, 
(ApoE) or more precisely E4 allele, who manifested 
moderate cognitive disorders had rapidly-developed 
dementia (46-48).         
 
Conclusions 
The dominant pathology in vascular neurocognitive 
disorder is cerebrovascular disease, the cognitive decline 
being associated with clinical neurological signs 
characteristic of cerebral lesions that can be focal, 
multifocal, diffuse, or in diverse combinations.  
The risk factors involved in the generation of a 
vascular neurocognitive disorder are similar to those for 
an ischemic or hemorrhagic cerebrovascular accident: 
arterial hypertension, diabetes mellitus, dyslipidemia, 
smoking, obesity, age, alcohol consumption, cerebral 
atherosclerosis, or arteriosclerosis. For this reason, 
efficient management of the vascular risk factors can 
prevent cognitive decline and dementia.  
Vascular neurocognitive disorder represents a 
heterogenous group of manifestations associated with the 
various types of cerebrovascular lesions, manifestations 
that progress through different stages during their 
evolution, up to the final phase of vascular 
neurocognitive disorder. The disorder is actually a 
memory disorder exacerbated by aphasia, apraxia, 
agnosia, and deterioration of executive functions, which 
then interfere with the patient’s daily activities. Criteria 
for the correct and complete diagnosis of vascular 
neurocognitive disorder have been updated, with the 
diagnosis algorithm involving both the NINDS-AIRENS 
criteria and those in DSM5.   
Understanding the interrelation among vascular risk 
factors, cerebrovascular disease, and the vascular 
neurocognitive disorder represents an ongoing challenge 
and an important step with respect to the diagnosis and 
treatment of the various types of cognitive disorders. 
Patients with cognitive disorders and especially those 
with vascular neurocognitive disorders are characterized 
by a higher degree of disability, a lower life quality, and 
a shorter life expectancy. Furthermore, the costs for their 
treatment and supervision under special conditions are 
high. 
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